Anavex Contracts FORENAP Pharma for Pre-Clinical Trials of ANAVEX 2-73 in Alzheimer’s Disease.

Geneva, Switzerland — September 30, 2009 — Anavex Life Sciences Corp. (“ANAVEX” or the “Company”) (OTCBB: AVXL) has selected FORENAP Pharma EURL (“FORENAP”) as the contract research organization (CRO) for Phase I clinical trials of ANAVEX 2-73, the company’s lead Alzheimer’s drug candidate.  FORENAP has been involved in pre-clinical and clinical research for 20 years…